BainĮffects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials, Katherine Tuttle, David Cherney, Samy Hadjadj, Thomas Idorn, Ofri Mosenzon, Vlado Perkovic, Soren Rassmussen, Benjamin Wolthers, and Stephen C. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation., Katherine Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl, Leigh Perreault, Sylvia E Rosas, Peter Rossing, Laura Sola, Volker Vallon, Christoph Wanner, and Vlado PerkovicĮffects Of Semaglutide On Chronic Kidney Disease Outcomes: A Post Hoc Pooled Analysis From The SUSTAIN 6 And PIONEER 6 Trials, Katherine Tuttle, David Cherney, Samy Hadjadj, Thomas Idorn, Ofri Mosenzon, Vlado Perkovic, Soren Rassmussen, Benjamin Wolthers, and Stephen C. Where do GLP-1 RAs Fit into the Management of Patients with Diabetes and CKD?, Katherine Tuttle The landscape of diabetic kidney disease transformed., Katherine Tuttle Revolution in the Management of Moderate to Severe CKD, Katherine Tuttle Impact of the COVID-19 pandemic on clinical research., Katherine Tuttle Cardiorenal–Metabolic Axis in Diabetes, Katherine Tuttleĭoing Better for Diabetes and Chronic Kidney Disease (CKD), Katherine TuttleĮmerging Options for the Management of CKD: Where Are We Now?, Katherine Tuttle

Dana maria huja